2023 World Conference on Lung Cancer (Posters)-P2.05. Association Between Immune-Related Adverse Events and Survival in a Contemporary Metastatic Non-Small Cell Lung Cancer Cohort

P2.05. Association Between Immune-Related Adverse Events and Survival in a Contemporary Metastatic Non-Small Cell Lung Cancer Cohort - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to examine the association between immune-related adverse events (irAEs) and survival in patients with metastatic non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICPis). The study analyzed data from the Alberta Immunotherapy Database (AID) and included patients who had completed at least one cycle of ICPis between March 2014 and November 2021.<br /><br />The study found that developing a clinically impactful irAE, such as those requiring ICPi delay/cessation or systemic steroids, improved overall survival (OS) and time to next treatment (TTNT) in metastatic NSCLC patients. This association was not compromised by hospitalization for severe toxicity.<br /><br />Baseline characteristics that were prognostic for irAE development included age under 60, ECOG performance status of 0, high levels of PDL-1, no bone metastases, normal levels of hemoglobin, albumin, and LDH, and a derived neutrophil to lymphocyte ratio of less than 3. However, gender, histology, driver mutation, treatment line, or type of ICPi were not prognostic.<br /><br />The study also found that patients with confirmed irAEs had longer OS and TTNT compared to those without irAEs. Hospitalized patients had similar survival outcomes to those whose irAEs were treated as outpatients. The incidence of irAEs remained independently associated with OS in the total cohort after adjusting for known prognostic characteristics.<br /><br />In summary, the study suggests that developing clinically impactful irAEs is associated with improved survival outcomes in metastatic NSCLC patients receiving ICPis. These findings support the potential benefit of irAEs as a predictive biomarker for response to ICPi therapy.

Asset Subtitle

Sarah Cook

Meta Tag

Speaker Sarah Cook

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

immune-related adverse events

survival

metastatic non-small cell lung cancer

immune checkpoint inhibitors

overall survival

time to next treatment

prognostic factors

PDL-1

confirmed irAEs

predictive biomarker